8 results about "Desmosome" patented technology

The disclosure provides methods of diagnosing, prognosing and stratifying cancers in a patient, comprising detecting elevated expression of desmoglein-2 (DSG-2) in a sample of the cancer and referencing that level to historic data to determine treatment regimen, stage, and prognosis of a patient.

The present invention provides a method and a pharmaceutical composition for treatment of skin diseases associated with accelerated comeodesmosomes degradation and / or weaker cell-cell adhesion, such as a peeling skin syndrome, Netherton syndrome, and atopic dermatitis.

A method for diagnosing facioscapulohumeral muscular dystrophy (FSHD) using one or more biomarkers is provided. More particularly, provided is a method for diagnosing FSHD in a subject, the method comprising detecting the presence of a biomarker or change in level of a biomarker in a biological sample from the subject, wherein the biomarker is wherein the biomarker is mannose binding lectin 2 (MBL2), junction plakoglobin (JUP), desmoplakin (DSP), tetranectin (CLEC3B), complement component 7 (C7), complement component 9 (C9), tenascin C (TNG), lumican (LUM), phosphatidylinositol-glycan-specific phospholipase D (GPLD1 ), complement component 4 binding protein, beta chain (C4BPB), carnosine dipeptidase (CNDP1), or immunoglobulin kappa variable 2-30 (IGKV2-30), or a combination of any two or more of MBL2, JUP, DSP, CLEC3B, C7, C9, TNG, LUM, GPLD1, C4BPB, CNDP1, or IGKV2-30. In some aspects, when the change in level of the biomarker is an increase in the level of MBL2, JUP, DSP, CLEC3B, C7, C9, TNG, and / or LUM, or a combination of any thereof, the subject is diagnosed as having FSHD. In some aspects, when the change in level of the biomarker is a decrease in the level of GPLD1, C4BPB, CNDP1, and / or IGKV2-30, or a combination of any thereof, the subject is diagnosed as having FSHD. Also provided is a method for determining efficacy of a therapeutic treatment for FSHD in a subject, the method comprising measuring the level of a biomarker in a biological sample from the subject before and after the treatment, and determining that the treatment is effective in treating FSHD if the level of the biomarker is decreased or increased relative to a reference level or to the level of the biomarker in the sample from the subject before treatment, wherein when the biomarker is mannose binding lectin 2 (MBL2), junction plakoglobin (JUP), desmoplakin (DSP), tetranectin (CLEC3B), complement component 7 (C7), complement component 9 (C9), tenascin C (TNG), or lumican (LUM), or a combination of any two or more of MBL2, JUP, DSP, CLEC3B, C7, C9, TNG, or LUM, the treatment is effective when the level of the biomarker decreases, or wherein when the biomarker is phosphatidylinositol-glycan-specific phospholipase D (GPLD1), complement component 4 binding protein, beta chain (C4BPB), carnosine dipeptidase (CNDP1), or immunoglobulin kappa variable 2-30 (IGKV2-30), or a combination of any two or more of GPLD1, C4BPB, CNDP1, or IGKV2-30, the treatment is effective when the level of the biomarker increases. In various aspects, the method further comprises treating the subject diagnosed with FSHD.

The invention belongs to the field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating post-infection irritable bowel syndrome as well as a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 10 to 15 parts of rhizoma atractylodis macrocephalae, 10 to 20 parts of radix paeoniae alba, 3 to 7 parts of pericarpium citri reticulatae, 5 to 15 parts of radix saposhnikoviae, 10 to 20 parts of folium microcotis, 10 to 20 parts of plumeria rubra, 5 to 15 parts of kapok, 25 to 35 parts of rhizoma smilacis glabrae and 5 to 15 parts of flos albiziae. Animal experiments show that the traditional Chinese medicine composition can effectively improve diarrhea phenotypes and depressive symptoms of rats with PI-IBS liver depression and spleen deficiency syndromes, relieve high sensitivity of viscera, recover a tight junction structure and a cell desmosome structure of colon, up-regulate cell TJ protein expression, recover Th1 / Th2 immune imbalance of blood, reduce the level of proinflammatory factors (TNF-alpha) in colon tissue, and improve the immunity of the rats. And the levels of LPS, DAO and D-LA in serum are up-regulated. Therefore, the traditional Chinese medicine composition disclosed by the invention can be used for effectively treating the liver depression and spleen deficiency syndrome of the irritable bowel syndrome after infection.

The present application relates to the use of a polypeptide or antibody binding fragment thereof capable of forming an antigen-antibody complex with a biological sample obtained from the patient in the preparation of a reagent or kit for detecting vascular endothelial cell damage; wherein the polypeptide or antibody binding fragment thereof comprises at least two selected from the following group: alpha enolase protein (ENO1), ankle protein 1 (TLN1), filamin-A (FLNA), desmosomal linker protein (AHNAK), desmosomal core glycoprotein-1 (DSG1), myosin light chain 1 (MYL1), heat shock protein 90 beta (HSP90AB1), cytoskeleton-associated protein 4 (CKAP4), membrane spike protein (MSN). The vascular endothelial cell autoantibody of the present application can be used to diagnose vascular endothelial cell damage by simply detecting the titer in serum, which has very great clinical application value.

The invention belongs to the technical field of daily-use chemistry, and particularly relates to a keratin regulating composition containing mandelic acid and having skin smoothing and brightening effects and application of the keratin regulating composition. The composition provided by the invention comprises mandelic acid, lactobionic acid, hydroxyethyl piperazine ethanesulfonic acid, lactobacillus / soybean milk fermentation product filtrate and lactobacillus fermentation lysate. According to the application, mandelic acid, lactobionic acid, hydroxyethyl piperazine ethanesulfonic acid, lactobacillus / soybean milk fermentation product filtrate and lactobacillus fermentation lysate are compounded, so that the activity of KLK family proteases, especially kallikrein 5 (KLK5), can be obviously promoted, the decomposition of desmosome between keratinocytes is promoted, epidermal cells lose cohesion and finally naturally fall off, and the effect of promoting the activity of KLK family proteases is achieved. The cutin exfoliation promoting effect is achieved, so that the problems of skin darkness, roughness, pore blockage, acne and the like are solved, the glossiness and fineness of the skin are improved, and healthy and bright skin is achieved.